Work

An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response

Year: 2026
Type: article
Abstract: Immune heterogeneity and metabolic remodeling frequently limit the efficacy of immunotherapy in lung adenocarcinoma (LUAD). To address this challenge, we integrated single-cell and bulk RNA sequencing analyses, pairing machine learning with preclinical models to develop the APOA5-correlated T-cell Signature (ACTsig), which effectively stratifies LUAD patients and predicts immunotherapeutic response. Moreover, We identified apolipoprotein A-V (APOA5) as a previously unrecognized tumor suppressor linking cholesterol homeostasis to the tumor immune ecosystem. Mechanistically, APOA5 deficiency induced intracellular cholesterol accumulation and MIF production. Cholesterol depletion and replenishment established a causal role for cholesterol accumulation in regulating MIF production, while MIF knockdown reversed APOA5-loss-induced T-cell exhaustion and recombinant MIF restored the phenotype. Meanwhile, CXCR4 blockade rescued APOA5-loss-induced T-cell exhaustion, supporting the functional involvement of the MIF receptor CXCR4 in this immunosuppressive phenotype. Finally, in silico drug screening identified fenofibrate, which, in combination with anti-PD-1 therapy, significantly suppressed tumor growth in APOA5-deficient models. Together, these findings establish ACTsig as a predictive biomarker for immunotherapy response and reveal an APOA5-cholesterol-MIF-CXCR4 axis underlying T-cell exhaustion.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $6,730
OpenAlex ID: W7233743133
FWCI:
Cites: 85
Cited by:
Related to: 10